5TCZ

NMR solution structure of engineered Protoxin-II analog


Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Calculated: 500 
  • Conformers Submitted: 20 
  • Selection Criteria: structures with the lowest energy 

wwPDB Validation   3D Report Full Report


This is version 1.0 of the entry. See complete history


Literature

Insensitivity to pain induced by a potent selective closed-state Nav1.7 inhibitor.

Flinspach, M.Xu, Q.Piekarz, A.D.Fellows, R.Hagan, R.Gibbs, A.Liu, Y.Neff, R.A.Freedman, J.Eckert, W.A.Zhou, M.Bonesteel, R.Pennington, M.W.Eddinger, K.A.Yaksh, T.L.Hunter, M.Swanson, R.V.Wickenden, A.D.

(2017) Sci Rep 7: 39662-39662

  • DOI: 10.1038/srep39662
  • Primary Citation of Related Structures:  
    5TCZ

  • PubMed Abstract: 
  • Pain places a devastating burden on patients and society and current pain therapeutics exhibit limitations in efficacy, unwanted side effects and the potential for drug abuse and diversion. Although genetic evidence has clearly demonstrated that the voltage-gated sodium channel, Nav1 ...

    Pain places a devastating burden on patients and society and current pain therapeutics exhibit limitations in efficacy, unwanted side effects and the potential for drug abuse and diversion. Although genetic evidence has clearly demonstrated that the voltage-gated sodium channel, Nav1.7, is critical to pain sensation in mammals, pharmacological inhibitors of Nav1.7 have not yet fully recapitulated the dramatic analgesia observed in Nav1.7-null subjects. Using the tarantula venom-peptide ProTX-II as a scaffold, we engineered a library of over 1500 venom-derived peptides and identified JNJ63955918 as a potent, highly selective, closed-state Nav1.7 blocking peptide. Here we show that JNJ63955918 induces a pharmacological insensitivity to pain that closely recapitulates key features of the Nav1.7-null phenotype seen in mice and humans. Our findings demonstrate that a high degree of selectivity, coupled with a closed-state dependent mechanism of action is required for strong efficacy and indicate that peptides such as JNJ63955918 and other suitably optimized Nav1.7 inhibitors may represent viable non-opioid alternatives for the pharmacological treatment of severe pain.


    Organizational Affiliation

    Janssen R&D, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Beta/omega-theraphotoxin-Tp2aA32Thrixopelma pruriensMutation(s): 0 
UniProt
Find proteins for P83476 (Thrixopelma pruriens)
Explore P83476 
Go to UniProtKB:  P83476
Protein Feature View
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Calculated: 500 
  • Conformers Submitted: 20 
  • Selection Criteria: structures with the lowest energy 
  • OLDERADO: 5TCZ Olderado

Structure Validation

View Full Validation Report




Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2017-01-18
    Type: Initial release